An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis

INTRODUCTION: Current medications for idiopathic pulmonary fibrosis (IPF) have not been shown to impact patient-reported outcome measures (PROMs), highlighting the need for accurate minimal clinically important difference (MCID) values. Recently published consensus standards for MCID studies support...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Mohleen, Veeraraghavan, Srihari, Martin, Greg S., Kempker, Jordan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521018/
https://www.ncbi.nlm.nih.gov/pubmed/34671666
http://dx.doi.org/10.1183/23120541.00142-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521018/
https://www.ncbi.nlm.nih.gov/pubmed/34671666
http://dx.doi.org/10.1183/23120541.00142-2021

Ejemplares similares